Juventas Cell Therapy Ltd (hereinafter referred as to JUVENTAS) is a biopharmaceutical company established in 2018, focusing on the research and development of innovative immune cell therapy products. JUVENTAS regards clinical requirements as the lodestar, constructs innovative research pipelines, and possesses effective development transformation platforms.Through professional and sophisticated production, QA, and QC system, we produce safe, highly-effective, and accessible immune cell therapy products for patients.
Currently, JUVENTAS owns a 1300㎡ research center in Beijing, a 1400㎡ institute complying GMP standard for immune cell therapy drug’s R&D transformation and production, also, our 7000㎡ GMP immune cell therapy drug production base is under construction.
On November 29, Center for Drug Evaluation (CDE), National Medical Products Administration (NMPA) officially approved two applications of JUVENTAS’ new drug clinical trial for CNCT 19 Cell Injection (anti-CD19 Chimeric Antigen Receptor T Cell Injection) to treat relapsed or refractory acute lymphoblastic leukemia and relapsed or refractory invasive B-cell non-Hodgkin’s lymphoma.
Lü Lu LuCEO
Ph.D. in Hematology.Fujian Medical University
Exchange visitor at New York Medical College (NYMC)
•Hematologist, 11 years of experience
•10 years of experience in innovative drug development and new product strategic planning in the field of blood and oncology
•Worked in the R&D center, new product planning and marketing departments of multinational companies, such as Novartis, Roche, AstraZeneca and MSD
•Instrumental in the successful launch and market expansion of groundbreaking cancer products
Master of International Pharmaceutical Engineering Management.Peking University.
MBA, Maryville University St. Louis, USA
20 years of experience in corporate management, human resources and project management in the pharmaceutical industry.
Zhang QiMedical Director
Ph.D. in Hematology, Institute of Hematology, Peking University People’s Hospital
• Clinician of Peking University People’s Hospital
• Clinical Medicine at Genzyme, Sanofi, CP Guojian and Genor Biopharma.
Sun JianhuiClinical Operation Director
Graduated from the College of Life Sciences of Nankai University
A former core leadership team member of the Pfizer (China) Clinical Trial Management Team, with extensive clinical trial experience in various fields and all phases
Deng YipingBiomarkers Development Director
Ph.D. in Pathology of the Joint training Project, Jilin University/University of California, San Diego
Former head of the Immuno-oncology diagnostic team of AstraZeneca.
Wang HaoRegulatory Affairs Director
Master of Tianjin University
More than 10 years of experience in drug registration of multinational pharmaceutical companies and successful submission and approval of multiple clinical approvals for Class 1 biopharmaceuticals.
Shi LinTechnical Director
Ph.D. in Internal Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College
10 years of experience in biological products development, transformation and quality management.
Wang YingQuality Assurance Director
More than 10 years of experience in multinational pharmaceutical companies, including years of quality management experience in GSK and Novozymes Biopharma.
Lu Guo QiuBeijing R&D Center Director
Ph.D. in Biochemistry and Molecular Biology, Peking Union Medical College
• Has been engaging in tumor cellular immunotherapy since graduation
• Rich experience in immune cell product development, laboratory management, GMP production, and quality control
• Currently in charge of the CAR-T product research and development
• Served as executive deputy general manager and technical director of CASI
Fu DingFinancial Director
China Certified Public Accountant (CPA) and Affiliate Member of AIA (AMIA)
• Engaged in finance for 20 years
• Years of financial management experience of retail groups and Internet entrepreneurial companies
• Experience in mergers and acquisitions, IPO, financing, etc.
Peng HuaMedical Manager
Ph.D. in Biochemistry and Molecular Biology, Peking Union Medical College (Chinese Academy of Medical Sciences)
• 5 years of experience in blood disease laboratory and blood transfusion department
• 3 years of experience in CAR-T industry
• Currently responsible for the development of clinical trial protocols and related medical affairs.